Código QR (código de barras bidimensional)

Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors

Summary: This phase 1b/2 clinical trial (NCT04775680) evaluated the safety, efficacy, pharmacokinetics and pharmacodynamics of ADG106, a ligand-blocking agonistic antibody targeting CD137 (4-1BB), combined with toripalimab in patients with advanced malignancies. ADG106 0.75–3 mg/kg plus toripalimab...

Fuld beskrivelse

Na minha lista:
Principais autores: Shaoyan Lin, Yuxiang Ma, Yongsheng Wang, Yunpeng Yang, Jinhui Xue, Yan Huang, Yuanyuan Zhao, Wenfeng Fang, Shaodong Hong, Yang Zhang, Qianwen Liu, Guizhong Liu, Xiaohong She, Jiping Zha, Songmao Zheng, Yan Li, Peter Luo, Li Zhang, Hongyun Zhao
Format: Artigo
Sprog:Inglês
Udgivet: Elsevier 2025-05-01
Serier:iScience
Fag:
Oncology
Clinical medicine
Therapeutics
Online adgang:http://www.sciencedirect.com/science/article/pii/S2589004225007588
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker